Sun Pharmaceutical Industries Limited — Board Meeting, 22-05-2025: Outcome of Board Meeting

Sun Pharma has announced a board meeting to approve the consolidated financial results for the quarter and year ended March 31, 2025. Q4 gross sales rose 8.5% YoY to Rs. 12,916 Cr, with EBITDA up 22.4%. Adjusted net profit grew 4.8% to Rs. 2,889 Cr, despite reported net profit dipping to Rs. 2,150 Cr. Full-year sales increased 9% to Rs. 52,041 Cr, driven by strong performance in India (+13.7%) and Global Specialty (+17.1%). The board proposed a final dividend of Rs. 5.50/share, resulting in a total FY25 dividend of Rs. 16/share. Ms. Vidhi Shanghvi joins as Whole-time Director; Mr. Sudhir Valia retires by rotation.